Browsing by Author "Basturk A."

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    The clinicopathological features and survival of Castleman disease: A multicenter Turkish study
    (Verduci Editore s.r.l, 2022) Yildiz J.; Bagci M.; Sayin S.; Kaya A.; Yilmaz F.; Ekinci O.; Dal M.S.; Basturk A.; Aydogdu I.; Albayrak M.; Dogan A.; Erkurt M.A.; Korkmaz S.; Ulas T.; Eser B.; Altuntas F.
    Objective: In this study, we aimed to investigate the clinicopathological features and survival of CD, which is quite rare and has many unknowns. Patients and Methods: This study was conducted by retrospectively evaluating patients diagnosed with CD in six different centers in Turkey. Results: The median age of 33 patients included in the study was 49 and 51.5% (n = 17) of these patients were women. 18 (54.5%) patients were in the hyaline vascular subtype and most of the patients were UCD (n = 20, 60.6%). The most common involvement region was head and neck (n = 19, 57.5%). The UCD group was younger than the MCD group (p=0.027). Visceral lymph node involvement was higher in MCD than in UCD (p=0.001). Similarly, it was observed that there was more hepatomegaly (p=0.035) and splenomegaly (p=0.013) in the MCD group. During the median 19.5 months follow-up period, there were no patients who died. Conclusions: It was observed that UCD and MCD are different clinical entities. Promising survival times can be achieved with surgical and systemic treatments in both subtypes of this extremely rare disease. However, this result should be supported by well-designed prospective comprehensive studies. © 2022 Verduci Editore s.r.l. All rights reserved.
  • No Thumbnail Available
    Item
    Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey
    (Taylor and Francis Ltd., 2023) Bakırtaş M.; Dal M.S.; Yiğenoğlu T.N.; Giden A.O.; Serin I.; Başcı S.; Kalpakci Y.; Korkmaz S.; Ekinci O.; Albayrak M.; Basturk A.; Ozatli D.; Dogu M.H.; Hacıbekiroglu T.; Çakar M.K.; Ulas T.; Miskioglu M.; Gulturk E.; Eser B.; Altuntas F.
    A multicenter, retrospective, observational study was conducted to explore effectiveness and safety of ixazomib plus lenalidomide with dexamethasone (IRd) in relapsed/refractory multiple myeloma (RRMM) patients following at least ≥ two lines of therapy. Patients’ treatment responses, overall response rate, progression-free survival rate, and adverse events were recorded. Mean age of 54 patients was 66.5 ± 9.1 years. There were 20 patients (37.0%) with progression. Median progression-free survival was 13 months in patients who received a median of three therapy lines in a 7.5-month follow-up period. Overall response rate was 38.5%. Of 54 patients, 19 (40.4%) had at least one adverse event, and nine (19.1%) had an adverse event of at least grade 3 or more. Of 72 adverse events observed in 47 patients, 68% were grade 1 or 2. Treatment was not stopped in any patient due to adverse events. IRd combination therapy was effective and safe in heavily treated RRMM patients. © 2023 Edizioni Scientifiche per l'Informazione su Farmaci e Terapia (Italian Society of Chemotherapy).
  • No Thumbnail Available
    Item
    International Forum: The Turkish perspective on apheresis activity: The Turkish apheresis registry report
    (Elsevier Ltd, 2023) Ozatli D.; Giden A.O.; Erkurt M.A.; Korkmaz S.; Basci S.; Ulas T.; Turgut B.; Yigenoglu T.N.; Hacibekiroglu T.; Basturk A.; Dal M.S.; Namdaroglu S.; Hindilerden F.; Hacioglu S.K.; Cagliyan G.A.; Ilhan G.; Kacmaz M.; Uysal A.; Merter M.; Ekinci O.; Dursun F.E.; Tekinalp A.; Demircioglu S.; Sincan G.; Acik D.Y.; Akdeniz A.; Ucar M.A.; Yeral M.; Ciftciler R.; Teke H.U.; Umit E.G.; Karakus A.; Bilen Y.; Yokus O.; Albayrak M.; Demir C.; Okan V.; Serefhanoglu S.; Kartı S.; Ozkurt Z.N.; Eser B.; Aydogdu I.; Kuku I.; Cagirgan S.; Sonmez M.; Ozet G.; Altuntas F.
    Therapeutic apheresis is an extracorporeal treatment that selectively removes abnormal cells or harmful substances in the blood that are associated with or cause certain diseases. During the last decades the application of therapeutic apheresis has expanded to a broad spectrum of hematological and non-hematological diseases due to various studies on the clinical efficacy of this procedure. In this context there are more than 30 centers performing therapeutic apheresis and registered in the apheresis database in Turkey. Herein, we, The Turkish Apheresis Registry, aimed to analyze some key articles published so far from Turkey regarding the use of apheresis for various indications. © 2023 Elsevier Ltd